Yeah, I get what you are suggesting, but I prefer the playbook from real activist investors, who get seats on the board and implement change from the inside, rather than suggestions from the outside. We have never heard a suggestion from him on the open market place, maybe some on here have, but all I have not
None of it makes sense to me, especially the options package for a cross T's & dot I's consultancy (mind boggling).
Video: Paradigm Biopharmaceuticals (ASX:PAR) conducting Phase 3 osteoarthritis trial, page-29
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
-0.005(1.96%) |
Mkt cap ! $87.44M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 25.0¢ | $13.08K | 51.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 133489 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 25012 | 2 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |